Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of the humanized 14.18 anti-GD2 monoclonal antibody (mAb) connected to interleukin-2 (IL210). It exerts its anti-tumor effects [1] through the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. This is achieved by the targeted binding of hu14.18-IL2 to GD2-expressing tumor cells, which facilitates subsequent interaction with Fc receptors on immune effector cells, as well as the stimulation of natural killer (NK) and T cells through their IL2 receptors.
説明 | Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of the humanized 14.18 anti-GD2 monoclonal antibody (mAb) connected to interleukin-2 (IL210). It exerts its anti-tumor effects [1] through the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. This is achieved by the targeted binding of hu14.18-IL2 to GD2-expressing tumor cells, which facilitates subsequent interaction with Fc receptors on immune effector cells, as well as the stimulation of natural killer (NK) and T cells through their IL2 receptors. |
別名 | hu14.18-IL2, EMD 273063, 14.18 mAb |
分子量 | N/A |
CAS No. | 2131168-99-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lorukafusp alfa 2131168-99-3 hu14.18-IL2 EMD 273063 14.18 mAb Inhibitor inhibitor inhibit